Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Expert Discusses Evolving Role of Chemotherapy in Hormone-Sensitive Prostate Cancer

October 27th 2016

Several recent trials have supported the use of chemotherapy in the frontline setting for patients with hormone-sensitive metastatic prostate cancer.

Intensified Radiotherapy Emerging as New Standard

October 26th 2016

Radiation therapy can be effectively delivered in more focused, intensive, and shorter-course treatment regimens that offer patients at least equivalent—and in some cases superior—outcomes in several tumor types, thus helping to mitigate challenging adverse effects of standard approaches.

Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer

October 26th 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.

FDA Updates Enzalutamide Label in mCRPC

October 21st 2016

The FDA has updated the label for enzalutamide in metastatic castration-resistant prostate cancer to include new data from the phase II TERRAIN study.

Dr. Luke Nordquist on Who Should Receive Radium-223

October 21st 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

October 17th 2016

Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.

Dr. Daniel Eidelberg Spratt on Risk Factors in Prostate Cancer

October 17th 2016

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses challenges regarding the classification of risk groups in prostate cancer.

Dr. Twardowski on Sequencing Therapies for Patients With mCRPC

October 14th 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, medical oncologist, discusses the challenge with sequencing therapies for patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers Hope to Breathe New Life Into Immunotherapy for Prostate Cancer

October 13th 2016

Since the auspicious 2010 FDA approval of sipuleucel-T as the first immunotherapy vaccine for cancer, advancement with immunotherapy has been slow in the field of prostate cancer.

Expert Discusses Bone-Targeted Agents and Other Developments in mCRPC

October 11th 2016

Przemyslaw W. Twardowski, MD, describes the available therapies for patients with advanced metastatic castration-resistant prostate cancer, including bone-targeted therapies; the work that still lies ahead with these treatments; and the challenges with finding biomarkers to help develop targeted agents.

Role of Chemotherapy Remains Strong in High-Risk Localized Prostate Cancer

October 11th 2016

Howard M. Sandler, MD, sheds light on maximizing outcomes for patients with locally advanced prostate cancer, the evolving role of chemotherapy, and the steps to take once disease turns metastatic.

Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer

October 10th 2016

Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.

No Benefit Observed From Combined Irradiation in Intermediate-Risk Prostate Cancer

October 7th 2016

The addition of external-beam radiotherapy to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease.

Dr. Zhang on Therapeutic Advancements in Prostate Cancer

October 7th 2016

Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.

Dr. Dorff on Role of Chemotherapy in mCRPC

October 6th 2016

Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.

H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer

October 5th 2016

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Dr. Micallef on NuQ Blood Tests in Prostate Cancer

October 5th 2016

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Stereotactic Radiation Potential Emerges in Prostate Cancer

September 28th 2016

Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.

Similar Survival Rates Reported Across Treatment Options for Localized Prostate Cancer

September 21st 2016

Treatment options for men with localized prostate cancer include active surveillance, radical prostatectomy, or external-beam radiotherapy, but in the Prostate Testing for Cancer and Treatment trial each therapy was associated with a low prostate-specific mortality rate of about 1%.

QOL in Men Undergoing Monitoring for Prostate Cancer Similar to Men With No Disease

September 19th 2016

Men with positive needle biopsy for prostate cancer who underwent active surveillance exhibited no difference in quality-of-life compared with men who had a negative prostate needle biopsy.